
Sandacanol
CAS No. 28219-61-6
Sandacanol( —— )
Catalog No. M34892 CAS No. 28219-61-6
Sandacanol(Sandranol) is a selective olfactory receptor (OR10H1) agonist. Sandacanol can induce cell cycle arrest and partial apoptosis in bladder cancer cells, and can reduce cell migration rate and proliferation rate.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
25MG | 35 | Get Quote |
![]() ![]() |
50MG | 48 | Get Quote |
![]() ![]() |
100MG | 65 | Get Quote |
![]() ![]() |
500MG | 153 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSandacanol
-
NoteResearch use only, not for human use.
-
Brief DescriptionSandacanol(Sandranol) is a selective olfactory receptor (OR10H1) agonist. Sandacanol can induce cell cycle arrest and partial apoptosis in bladder cancer cells, and can reduce cell migration rate and proliferation rate.
-
DescriptionSandacanol is a specific agonist of olfactory receptor (OR10H1). Sandacanol induces cell cycle arrest and some apoptosis in bladder cancer cells.
-
In VitroSandacanol (50, 100, 300, 500, and 700 μM; 24 or 48 h) treatment significantly diminishes cell viability, cell proliferation and migration and induces a limited degree of apoptosis in BFTC905 bladder cancer cells.
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number28219-61-6
-
Formula Weight208.34
-
Molecular FormulaC14H24O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOCC(=CCC1CC=C(C)C1(C)C)CC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lea Weber, et al. Characterization of the Olfactory Receptor OR10H1 in Human Urinary Bladder Cancer. Front Physiol. 2018 May 16;9:456.?
molnova catalog



related products
-
Kinsenoside;(+)-Kins...
Kinsenoside shows significant antihepatotoxic and anti-inflammatory activities. Kinsenoside could be useful for repairing beta cells in pancreatic islet injury as well as improving its function it could promote the glucose tolerance of acute glucose increase in both diabetic and normal healthy rats.
-
TD52
TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter.
-
Polygalacin D
Polygalacin D shows anti- proliferation, anti-inflammary, and hepatoprotective activities.